To demonstrate the in vivo efficacy of monalizumab in conjunction with intratumoral delivery of human NK cells, transfected HLA‐Ehigh tumor cells were subcutaneously xenografted in Rag2−/‐IL2Rγ−/− immunodeficient mice and 7 days later when tumors reached approximately 40 mm3, mice were intratumorally co‐injected with activated human NK cells with or without monalizumab or control antibody. This evidence concerns the gene RAG2 and neoplasm.